International Clinical Trial: A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)

Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07889362) titled 'A Study to Learn About the Effects of Felzartamab on the Kidneys of Adults With Immunoglobulin A Nephropathy (IgAN)' on Oct. 16.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Biogen

Condition: Immunoglobulin A Nephropathy

Intervention: Drug: Felzartamab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: November 16, 2026

Target Sample Size: 25

To know more, visit https://clinicaltrials.gov/study/NCT07889362

Disclaimer: Curated by HT Syndication....